Cutaneous Melanoma – CDKN2A and CDK4 Genetic Testing

Product detailed description

Hereditary melanoma genetic testing (CDKN2A and CDK4) helps identify inherited genetic variants associated with an increased risk of cutaneous malignant melanoma, a serious form of skin cancer that develops from pigment-producing cells called melanocytes. Certain inherited genetic changes can significantly increase melanoma susceptibility, particularly in families with multiple cases of the disease.

The test focuses on the CDKN2A and CDK4 genes, which play important roles in regulating cell division and growth. Pathogenic variants in these genes may disrupt normal cell cycle control and increase the inherited risk of developing cutaneous melanoma.

CDKN2A is one of the most important genes associated with hereditary melanoma. Pathogenic variants in CDK4 are less common but can also contribute to familial melanoma susceptibility.

What does the genetic test analyze?

• CDKN2A gene – genetic variants associated with an increased risk of hereditary melanoma.

• CDK4 gene – variants that may affect cell cycle regulation and increase melanoma susceptibility.

• Inherited skin cancer predisposition – genetic factors associated with familial cutaneous melanoma.

• Familial genetic risk – information that may also be relevant to biological family members.

Who may benefit from hereditary melanoma genetic testing?

• Individuals with multiple cases of melanoma in their family.

• Patients who have developed multiple primary melanomas.

• People diagnosed with melanoma at an unusually young age, particularly with a family history of the disease.

• Families with a history of both melanoma and pancreatic cancer.

• Individuals referred for genetic testing by a dermatologist, oncologist, or clinical geneticist.

What can the results reveal?

The CDKN2A and CDK4 genetic test may identify inherited pathogenic variants associated with an increased susceptibility to cutaneous melanoma. A positive result can help healthcare professionals develop personalized prevention and surveillance strategies, including regular dermatological examinations and genetic counseling for family members.

Certain pathogenic variants in CDKN2A are also associated with an increased risk of pancreatic cancer, which may require additional specialist surveillance.

Important: A positive genetic result does not mean melanoma will necessarily develop, while a negative result does not eliminate the possibility of skin cancer. Risk is also influenced by other genetic factors, skin type, family history, and UV exposure. This test does not diagnose existing melanoma and does not replace regular dermatological examinations. Testing decisions and results should be discussed with a qualified genetics specialist.